Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

yttrium Y 90 clivatuzumab tetraxetan

A radioimmunoconjugate comprised of the humanized monoclonal antibody HuPAM4, directed against the pancreatic cancer antigen MUC1, that is conjugated to the chelating agent tetra-azacyclododecanetetra-acetic acid (DOTA) and radiolabeled with the beta-emitting radioisotope Yttrium Y90. Yttrium Y 90 clivatuzumab tetraxetan binds to tumor cells expressing MUC1 antigen, selectively delivering a cytotoxic dose of beta radiation.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:90Y-hPAM4
hPAM4-DOTA
yttrium Y 90 DOTA monoclonal antibody HuPAM4
Abbreviation:Y90 DOTA MOAB HuPAM4
Code name:IMMU-107
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search